8-KLeadership Changes

Guardant Health, Inc. 8-K Report, Executive Changes (Jun 13, 2019)

Filed June 13, 2019For Securities:GH

Summary

Guardant Health, Inc. (GH) announced on June 13, 2019, the departure of Leena Das-Young, Pharm. D., Chief LUNAR Officer and General Manager, for personal reasons. Dr. Das-Young's last day of employment with the company is June 18, 2019. This announcement is made under Item 5.02 of the 8-K filing, detailing departures of directors or certain officers. Investors should note that while Dr. Das-Young's departure from a key leadership role may raise initial questions, the company states it is for personal reasons. She will continue to serve through June 18th, allowing for a transition period. Dr. Das-Young is eligible for benefits under the Company’s Executive Severance Plan, along with previously provided relocation benefits, which are standard in such executive transitions and typically do not indicate operational distress.

Key Highlights

  • 1Leena Das-Young, Pharm. D., Chief LUNAR Officer and General Manager, is departing Guardant Health.
  • 2The departure is stated to be for personal reasons.
  • 3Dr. Das-Young's last day with the company is June 18, 2019.
  • 4The departure is effective shortly after the filing date of June 13, 2019.
  • 5Dr. Das-Young is entitled to benefits under the Company’s Executive Severance Plan.
  • 6She will also retain certain previously provided relocation benefits.

Frequently Asked Questions

Leena Das-Young, Pharm. D., served as the Chief LUNAR Officer and General Manager at Guardant Health.

According to the filing, Dr. Das-Young is leaving for personal reasons.

Her last day of service with Guardant Health is June 18, 2019.

Yes, in exchange for a customary release of claims, Dr. Das-Young is entitled to certain benefits under the Company’s Executive Severance Plan, in addition to retaining certain relocation benefits.